vs
帕可Bio（PACB）与沃特世（WAT）财务数据对比。点击上方公司名可切换其他公司
沃特世的季度营收约是帕可Bio的20.9倍（$932.4M vs $44.6M）。沃特世净利率更高（24.2% vs -90.4%，领先114.6%）。帕可Bio同比增速更快（13.8% vs 6.8%）。过去两年沃特世的营收复合增速更高（21.0% vs 7.3%）
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
沃特世是总部位于美国马萨诸塞州米尔福德的企业，面向生命科学、材料、食品等行业，提供色谱、质谱、实验室信息学、流变测量领域所用的分析仪器及配套软件，为各领域的检测、研发等工作提供可靠技术支持。
PACB vs WAT — 直观对比
营收规模更大
WAT
是对方的20.9倍
$44.6M
营收增速更快
PACB
高出7.0%
6.8%
净利率更高
WAT
高出114.6%
-90.4%
两年增速更快
WAT
近两年复合增速
7.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $44.6M | $932.4M |
| 净利润 | $-40.4M | $225.2M |
| 毛利率 | 37.1% | 61.1% |
| 营业利润率 | -92.3% | 29.0% |
| 净利率 | -90.4% | 24.2% |
| 营收同比 | 13.8% | 6.8% |
| 净利润同比 | -1802.7% | -2.7% |
| 每股收益（稀释后） | $-0.11 | $3.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PACBWAT
| Q4 25 | $44.6M | $932.4M | ||
| Q3 25 | $38.4M | $799.9M | ||
| Q2 25 | $39.8M | $771.3M | ||
| Q1 25 | $37.2M | $661.7M | ||
| Q4 24 | $39.2M | $872.7M | ||
| Q3 24 | $40.0M | $740.3M | ||
| Q2 24 | $36.0M | $708.5M | ||
| Q1 24 | $38.8M | $636.8M |
净利润PACBWAT
| Q4 25 | $-40.4M | $225.2M | ||
| Q3 25 | $-38.0M | $148.9M | ||
| Q2 25 | $-41.9M | $147.1M | ||
| Q1 25 | $-426.1M | $121.4M | ||
| Q4 24 | $2.4M | $231.4M | ||
| Q3 24 | $-60.7M | $161.5M | ||
| Q2 24 | $-173.3M | $142.7M | ||
| Q1 24 | $-78.2M | $102.2M |
毛利率PACBWAT
| Q4 25 | 37.1% | 61.1% | ||
| Q3 25 | 41.4% | 59.0% | ||
| Q2 25 | 36.9% | 58.3% | ||
| Q1 25 | -3.7% | 58.2% | ||
| Q4 24 | 25.6% | 60.1% | ||
| Q3 24 | 25.0% | 59.3% | ||
| Q2 24 | 16.5% | 59.3% | ||
| Q1 24 | 29.1% | 58.9% |
营业利润率PACBWAT
| Q4 25 | -92.3% | 29.0% | ||
| Q3 25 | -101.1% | 24.0% | ||
| Q2 25 | -112.8% | 24.4% | ||
| Q1 25 | -1154.5% | 22.9% | ||
| Q4 24 | -390.1% | 33.5% | ||
| Q3 24 | -160.3% | 28.5% | ||
| Q2 24 | -488.3% | 26.7% | ||
| Q1 24 | -209.6% | 21.0% |
净利率PACBWAT
| Q4 25 | -90.4% | 24.2% | ||
| Q3 25 | -98.9% | 18.6% | ||
| Q2 25 | -105.4% | 19.1% | ||
| Q1 25 | -1146.8% | 18.3% | ||
| Q4 24 | 6.0% | 26.5% | ||
| Q3 24 | -151.9% | 21.8% | ||
| Q2 24 | -481.3% | 20.1% | ||
| Q1 24 | -201.4% | 16.0% |
每股收益（稀释后）PACBWAT
| Q4 25 | $-0.11 | $3.76 | ||
| Q3 25 | $-0.13 | $2.50 | ||
| Q2 25 | $-0.14 | $2.47 | ||
| Q1 25 | $-1.44 | $2.03 | ||
| Q4 24 | $-0.44 | $3.88 | ||
| Q3 24 | $-0.22 | $2.71 | ||
| Q2 24 | $-0.64 | $2.40 | ||
| Q1 24 | $-0.29 | $1.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $279.5M | $587.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $5.3M | $2.6B |
| 总资产 | $784.1M | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.55× |
8季度趋势，按日历期对齐
现金及短期投资PACBWAT
| Q4 25 | $279.5M | $587.8M | ||
| Q3 25 | $298.7M | $459.1M | ||
| Q2 25 | $314.7M | $367.2M | ||
| Q1 25 | $343.1M | $382.9M | ||
| Q4 24 | $389.9M | $325.4M | ||
| Q3 24 | $471.1M | $331.5M | ||
| Q2 24 | $509.8M | $327.4M | ||
| Q1 24 | $561.9M | $338.2M |
总债务PACBWAT
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PACBWAT
| Q4 25 | $5.3M | $2.6B | ||
| Q3 25 | $36.1M | $2.3B | ||
| Q2 25 | $61.5M | $2.2B | ||
| Q1 25 | $91.6M | $2.0B | ||
| Q4 24 | $506.6M | $1.8B | ||
| Q3 24 | $453.1M | $1.6B | ||
| Q2 24 | $492.7M | $1.4B | ||
| Q1 24 | $649.0M | $1.3B |
总资产PACBWAT
| Q4 25 | $784.1M | $5.1B | ||
| Q3 25 | $803.2M | $4.9B | ||
| Q2 25 | $825.5M | $4.7B | ||
| Q1 25 | $860.8M | $4.6B | ||
| Q4 24 | $1.3B | $4.6B | ||
| Q3 24 | $1.5B | $4.5B | ||
| Q2 24 | $1.5B | $4.4B | ||
| Q1 24 | $1.7B | $4.5B |
负债/权益比PACBWAT
| Q4 25 | — | 0.55× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.89× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.1M | $164.6M |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | — |
| 自由现金流率自由现金流/营收 | -44.6% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.73× |
| 过去12个月自由现金流最近4个季度 | $-114.1M | — |
8季度趋势，按日历期对齐
经营现金流PACBWAT
| Q4 25 | $-19.1M | $164.6M | ||
| Q3 25 | $-18.7M | $187.3M | ||
| Q2 25 | $-29.4M | $41.1M | ||
| Q1 25 | $-44.1M | $259.6M | ||
| Q4 24 | $-30.6M | $240.1M | ||
| Q3 24 | $-45.5M | $204.6M | ||
| Q2 24 | $-54.3M | $54.5M | ||
| Q1 24 | $-75.7M | $262.9M |
自由现金流PACBWAT
| Q4 25 | $-19.9M | — | ||
| Q3 25 | $-18.8M | — | ||
| Q2 25 | $-29.9M | — | ||
| Q1 25 | $-45.4M | — | ||
| Q4 24 | $-32.3M | — | ||
| Q3 24 | $-46.3M | — | ||
| Q2 24 | $-55.7M | — | ||
| Q1 24 | $-79.6M | — |
自由现金流率PACBWAT
| Q4 25 | -44.6% | — | ||
| Q3 25 | -48.9% | — | ||
| Q2 25 | -75.3% | — | ||
| Q1 25 | -122.3% | — | ||
| Q4 24 | -82.3% | — | ||
| Q3 24 | -115.7% | — | ||
| Q2 24 | -154.8% | — | ||
| Q1 24 | -205.0% | — |
资本支出强度PACBWAT
| Q4 25 | 1.9% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 10.0% | — |
现金转化率PACBWAT
| Q4 25 | — | 0.73× | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 2.14× | ||
| Q4 24 | -12.93× | 1.04× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 2.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
WAT
暂无分部数据
